Cognitive diseases targeted

A new Belgian company has been launched to develop therapies for cognitive disorders using intellectual property from UCB SA. The company has received Series A financing of €17 million from a syndicate of Belgian and international investors.

Full text available to subscribers only. Click here for information on subscribing to MedNous.